[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626990":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":58,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Haseki Training and Research Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous Dexamethasone Group",null,"Patients undergoing primary total knee arthroplasty who receive dexamethasone intravenously according to the routine perioperative protocol of the operating surgeon (8 mg IV preoperatively and 4 mg IV postoperatively).",[13],"Other: Routine perioperative management",{"label":15,"type":10,"description":16,"interventionNames":17},"Oral Dexamethasone Group","Patients undergoing primary total knee arthroplasty who receive dexamethasone orally according to the routine perioperative protocol of the operating surgeon (8 mg oral preoperatively and 4 mg oral postoperatively).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Control Group (No Dexamethasone)","Patients undergoing primary total knee arthroplasty who do not receive dexamethasone as part of the routine perioperative management.",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Routine perioperative management","This is a prospective observational cohort study. No intervention is assigned by the investigators. Patients are managed according to the routine perioperative dexamethasone protocols of the surgeon chosen by the patient.\n\nOne cohort receives intravenous dexamethasone (8 mg preoperatively and 4 mg postoperatively), one cohort receives oral dexamethasone (8 mg preoperatively and 4 mg postoperatively), and a control cohort receives no dexamethasone. All other perioperative and postoperative treatments are provided according to standard institutional practice and are not influenced by study participation.",[19,9,15],[28],{"name":29,"affiliation":30,"role":31},"Mehmet Ersin, Associate Professor","Sultangazi Haseki Training and Research Hospital","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Atahan Eryilmaz, Resident Physician","CONTACT","+90 552 609 9055","dratahaneryilmaz@gmail.com",{"name":29,"role":35,"phone":39,"phoneExt":10,"email":40},"+90 507 788 60 54","drmehmetersin@gmail.com",[42],{"facility":30,"status":43,"city":44,"state":44,"zip":45,"country":46,"countryCode":10,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Istanbul","34200","Turkey (Türkiye)",{"type":48,"coordinates":49},"Point",[50,51],28.94966,41.01384,{"lat":51,"lon":50},[54,57],{"name":34,"role":35,"phone":55,"phoneExt":10,"email":56},"+90552 609 9055","atahanerylmaz@yahoo.com",{"name":29,"role":35,"phone":39,"phoneExt":10,"email":40},{"type":31,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Mehmet Ersin","Associate Professor of Orthopaedics and Traumatology","100626990","oral-vs-intravenous-dexamethasone-in-total-knee-arthroplasty-100626990",false,"NCT07442812","Oral vs Intravenous Dexamethasone in Total Knee Arthroplasty","The Role of Dexamethasone in Total Knee Arthroplasty: Effects of Oral and Intravenous Administration on Early Postoperative Pain and Mobilization","TKA","Inclusion Criteria:\n\n* Age between 50 and 80 years\n* Diagnosis of primary knee osteoarthritis (primary gonarthrosis)\n* Scheduled for elective primary total knee arthroplasty\n* ASA physical status I or II\n* Ability to ambulate independently (with or without assistive devices) preoperatively\n* Ability to understand study procedures and complete pain and functional assessments\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Revision total knee arthroplasty\n* History of knee joint infection\n* Inflammatory arthritis (e.g., rheumatoid arthritis)\n* Chronic systemic corticosteroid use\n* Uncontrolled diabetes mellitus\n* Known endocrine disorders affecting glucose metabolism\n* Active infection at any site\n* Known hypersensitivity to corticosteroids\n* Severe hepatic, renal, or cardiac disease\n* Neurological or musculoskeletal disorders affecting gait or balance\n* Inability or unwillingness to comply with study procedures","ALL","50 Years","80 Years",{"count":73,"type":74},270,"ESTIMATED","OBSERVATIONAL","This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol.\n\nThe primary objective is to assess early postoperative recovery in terms of pain intensity, functional mobility, and knee joint range of motion. Secondary objectives include evaluation of inflammatory response, postoperative metabolic changes, opioid requirement, and the severity of postoperative nausea and vomiting (PONV).\n\nGroup allocation is non-randomized and determined solely by the standard perioperative management approach routinely applied by the surgeon selected by the patient. No additional interventions are introduced for research purposes. All outcomes are assessed prospectively during the early postoperative period.",[78,79,80],"Knee Osteoarthritis","Gonarthrosis; Primary","Total Knee Arthroplasty",[80,82,78,83,84],"Intravenous Dexamethasone","Gonarthrosis","Multimodal Analgesia","2026-05-19",{"date":87,"type":88},"2026-05-20","ACTUAL",{"date":90,"type":88},"2026-03-31",{"date":92,"type":74},"2027-10",{"name":5,"class":6},1]